(Q31145309)

29 June 2017

1 reference

title

Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism (English)

1 reference

29 June 2017

Effects of doxazosin on serum lipids: A review of the clinical data and molecular basis for altered lipid metabolism (English)

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Cardiology and cardiovascular medicine

3 December 2022

main subject

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

3 December 2022

author name string

J. L. Pool

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1824647

3 December 2022

language of work or name

English

0 references

publication date

1 January 1991

1 reference

full work available at URL

29 June 2017

https://api.elsevier.com/content/article/PII:000287039190853A?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

https://api.elsevier.com/content/article/PII:000287039190853A?httpAccept=text/plain

3 December 2022

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

3 December 2022

published in

American Heart Journal

1 reference

29 June 2017

121

1 reference

29 June 2017

251-9; discussion 259-60

1 reference

29 June 2017

1 Pt 2

1 reference

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

29 June 2017

1

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application

3 December 2022

2

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Management of multiple risk factors for coronary heart disease in patients with hypertension

3 December 2022

3

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Multivariate analysis of the relationship of seven variables to blood pressure: Findings of the Chicago Heart Association Detection Project in Industry, 1967–1972

3 December 2022

4

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. The pooling project research group

3 December 2022

5

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Need to prevent and control high-normal and high blood pressure, particularly so-called "mild" hypertension: epidemiological and clinical data

3 December 2022

6

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Preliminary results of the Norwegian doxazosin postmarketing surveillance study: A twelveweek experience

3 December 2022

7

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Doxazosin: a study in a cohort of patients with hypertension in general practice--an interim report.

3 December 2022

8

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

An open, noncomparative study of doxazosin in essential hypertension: experience in general practice in The Netherlands

3 December 2022

9

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Clinical experience with doxazosin in general medical practice in New Zealand

3 December 2022

10

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Treating hypertension and cardiovascular risk: are there trade-offs?

3 December 2022

11

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Plasma lipoprotein levels in treated and untreated hypertensive men and women. The National Heart Foundation of Australia Risk Factor Prevalence Study

3 December 2022

13

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Antihypertensive treatment and serum lipoproteins

3 December 2022

14

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. Hypertension Detection and Follow-up Program Cooperative Group

3 December 2022

17

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Mortality findings for stepped-care and referred-care participants in the hypertension detection and follow-up program, stratified by other risk factors. The Hypertension Detection and Follow-up Program Cooperative Research Group

3 December 2022

18

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

The Oslo study: CHD risk factors, socioeconomic influences, and intervention

3 December 2022

19

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party

3 December 2022

21

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Coronary heart disease in the Medical Research Council trial of treatment of mild hypertension. Medical Research Council Working Party on Mild Hypertension

3 December 2022

22

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial

3 December 2022

25

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension

3 December 2022

26

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension

3 December 2022

27

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

The antihypertensive effects of doxazosin: a clinical overview

3 December 2022

28

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension

3 December 2022

29

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

A 24-week multicenter double-blind study of doxazosin and hydrochlorothiazide in patients with mild to moderate essential hypertension

3 December 2022

30

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension

3 December 2022

31

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension

3 December 2022

32

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins

3 December 2022

33

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension

3 December 2022

34

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

A double-blind parallel trial to assess the efficacy of doxazosin, atenolol and placebo in patients with mild to moderate systemic hypertension

3 December 2022

35

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension

3 December 2022

36

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension

3 December 2022

37

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.

3 December 2022

38

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension

3 December 2022

39

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Efficacy and safety of doxazosin in hypertension therapy

3 December 2022

40

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up

3 December 2022

41

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension

3 December 2022

42

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Clinical experience with doxazosin in general medical practice in the Netherlands

3 December 2022

43

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

A long-term study of doxazosin in the treatment of mild or moderate essential hypertension in general medical practice

3 December 2022

44

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol

3 December 2022

45

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Doxazosin in the treatment of essential hypertension in general medical practice in Latin America

3 December 2022

46

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension

3 December 2022

47

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by by β-blockers

3 December 2022

48

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension

3 December 2022

49

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

New alpha 1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance

3 December 2022

51

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

New developments in alpha-adrenergic receptor pharmacology: Implications for the initial treatment of hypertension

3 December 2022

52

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Regulation of plasma cholesterol by lipoprotein receptors

3 December 2022

53

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension: An ex vivo study

3 December 2022

58

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Doxazosin increases low density lipoprotein receptor activity.

3 December 2022

59

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Effect of doxazosin on cholesterol synthesis in cell culture

3 December 2022

60

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Effects of doxazosin on lipids, lipoprotein lipases, and cholesterol synthesis in the golden hamster

3 December 2022

61

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Inhibition of hepatic cholesterol synthesis by the alpha 1-adrenoceptor blocker doxazosin in the hypercholesterolemic golden hamster

3 December 2022

62

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Effects of doxazosin and other antihypertensives on serum lipid levels and lipoprotein lipase in the C57BR/cdJ mouse

3 December 2022

64

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Influence of doxazosin on lipid transport in rats and hamsters

3 December 2022

67

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Göteborg, Sweden

3 December 2022

68

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

Background and design of the new U.S. trial on diet and drug treatment of "mild" hypertension (TOMHS)

3 December 2022

69

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90853-A

3 December 2022

Identifiers

1 reference

29 June 2017

1 reference